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ABSTRACT
Background: An accurate estimation of renal function in children is important in 
optimising the dose of many drugs used in paediatric oncology for allowing clinical 
monitoring of the nephrotoxic effects of cytotoxic agents such as cisplatin. The 
glomerular filtration rate (GFR) is widely accepted as the best index of renal function 
in patients. Chemotherapy is the mainstay of treatment in the paediatric oncology  
unit at the Kenyatta National Hospital.
Objectives: To determine the glomerular filtration rate profiles of paediatric oncology 
patients and to assess changes that had occured over a period of at least six months of 
continuing cancer chemotherapy.  
Design: Cross-sectional hospital based survey. 
Setting: General Paediatric wards, including Paediatric Oncology and Paediatric 
Ophthalmology ward. Kenyatta National Hospital, Nairobi, Kenya.
Subjects: Paediatric patients who had an established diagnosis of cancer and had been 
on chemotherapy for at least six months.
Results: Out of the 115 children enrolled in the study 43 had abnormal kidney function. 
This gave a prevalence of 37% (95%CI 28-46).The other 72 children had normal kidney 
function. Patients aged less than five years and those with solid tumors had a higher 
likelihood of having an abnormal GFR compared to their older counterparts and those 
with lymphomas and leukemias.
Conclusions: Monitoring of GFR should be done regularly as decline occurs as one 
continues on chemotherapy especially for the ones below five years and those with 
solid malignancies.
INTRODUCTION
Globally cancer-related deaths account for 13% 
annually and 70% of these are in the low- and middle-
income countries (1).Worldwide, the annual number 
of new cases of childhood cancer exceeds 200,000 
and more than 80% of these are from the developing 
world (2).  The incidence of childhood cancer in most 
populations in the world ranges from 75 to 150 per 
million children per year(3).
 It is estimated that the annual frequency of 
childhood cancers at Kenyatta National Hospital 
(KNH) is 125 cases per year. A review of some 
childhood cancers at KNH by Macharia in 1996 (3) 
found hospital based prevalence to be 1.27%.  
  The most common approach to cancer treatment 
is by combination therapy in which various modalities 
of surgery, radiotherapy and chemotherapy are used 
to eradicate both the primary neoplasm and metastatic 
lesions. At Kenyatta National Hospital, a multimodal 
approach is used for the treatment of the various 
paediatric cancers. The most widely used modality 
in pediatric cancer therapy is chemotherapy. Most of 
the cytotoxic drugs for childhood cancer are selected 
from several classes of agents, including alkylating 
agents, antimetabolites, antibiotics, hormones, plant 
alkaloids and topoisomerase inhibitors. Therapy 
nearly always involves combinations of drugs, such 
as:
 vincristine, doxorubicin or dactinomycin and •	
cyclophosphamide(VAC)  and
cyclophosphamide, doxorubicin , vincristine and •	
prednisone(CHOP)
 Renal failure remains an important complication 
of cancer and its treatment and this is often 
multifactorial in origin. These may include cancer 
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cachexia, cancer chemotherapy, concomitant use 
of other nephrotoxic drugs eg gentamycin and 
investigations involving use of radiocontrast media. 
Nephrotoxicity is an inherent adverse effect of certain 
anticancer drugs and has been shown to be a leading 
cause of renal compromise in oncology patients 
(4). Measurement of renal function is important in 
monitoring the nephrotoxic effects of oncology drugs 
such as cisplatin and ifosfamide (5). Assessment of 
the toxicity caused by chemotherapy in children with 
cancer has become more important as the number of 
long-term survivors has continued to increase.  It is 
vital to monitor both acute life-threatening adverse 
effects and long-term toxicity that may impair the 
child’s development and cause permanent morbidity. 
At Kenyatta National Hospital, the main referral 
facility in the country, a multimodal approach is used 
for the treatment of the various paediatric cancers. 
The most widely used modality in pediatric cancer 
therapy is chemotherapy.
MATERIALS AND METHODS 
This was a cross-sectional hospital based study of 
paediatric oncology patients aged less than 12yrs who 
had	a	confirmed	histologic	diagnosis	of	cancer	and	had	
been on chemotherapy for at least 6 months. Patients 
were seen between May 1st 2010 and 31st October 
2010 in the General Paediatrics wards, Paediatric 
Ophthalmology ward, the Paediatric Oncology ward 
and Hemato-oncology clinic at Kenyatta National 
Hospital,Nairobi.
 Paediatric patients who met the inclusion 
criteria were recruited and were enrolled into the 
study following obtaining of consent/assent.  Blood 
samples to measure serum creatinine were taken 
and sent to the renal laboratory in the renal unit at 
the Kenyatta National Hospital for analysis. The 
estimated GFR(eGFR )was determined from the 
Schwartz formula as follows:
   eGFR   =          k*Height
                      serum creatinine
Height represents the body height measured in 
centimeters, and Screat is the serum creatinine. The 
constant K is directly proportional to the muscle 
component of body, and varies with age. The value 
for k is 0.33 in premature infants, 0.45 for term infants 
through	 the	first	 year	 of	 life,	 0.55	 in	 children	 and	
adolescent girls, and 0.7 in adolescent boys, estimated 
glomerular	filtration	rates	were	tabulated.		
  Information on patient characteristics 
(age,sex,height and weight) and disease 
specifics(diagnosis,	treatment	regime	and	duration	
of treatment )  for each patient were recorded.  Files 
were studied and pre-treatment creatinine levels were 
retrieved.  Different malignancies, chemotherapeutic 
agents and age groups, cumulative doses of drugs 
were variables from which statistically correct 
conclusions were drawn. Data were entered in a 
preformatted data sheet in MS Access database and 
analysed using Staview stastistical package and 
analysis using Intercooled Stata version 9.0. Student 




From May to October 2010, a total of 115 patients on 
childhood cancer chemotherapeutic treatment had 
their GFR evaluated. Their median age was seven 
years and the range was between four to nine years.
Out of 115 children 60% of them were males (male: 
female ratio of 1.5:1) (Table 1).The median courses of 
chemotherapy treatment was 11 courses (Range 8-13 
courses). Majority of the patients in the study were 
from the Central and Eastern Province. Proximity 




Factor Frequency Median /Percentage
Age (in years)
Median  70
Range 2 to 12
<5 30 26.1•	





Number of courses received 11.0 (8-13) 
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The spectrum of malignancies seen included 
Leukemia in 43(37%) children, followed by 
Burkitts lymphoma 18(16%), Wilms tumor 
and Rhabdomyosarcoma 14(12%) each. Other 
malignancies were Retinoblastoma, Kaposi sarcoma, 
Hodgkin’s Lymphoma and other solid tumors 
(Neuroblastoma, Osteogenic sarcoma and Yolk 
Figure 1




















































































Glomerular	 filtration	 rates	 of	 children	 on	 cancer	
chemotherapy at Kenyatta National Hospital out 
of the 115 children enrolled in the study 43 had 
Figure 2
GFR after Chemotherapy
sac tumors). Children in the age group of had 
the highest incidence of malignancies; the most 
common being lymphoblastic leukemia, Burkitt’s 
lymphoma, rhabdomyosarcoma and wilms tumor. 
Lymphoblastic Leukemia was the most common 
malignancy in all the age groups. 
abnormal kidney function. This gave a prevalence 
of 37% (95%CI 28-46) as shown in Figure 2.The other 
72 children had normal kidney function.
Normal Gfr,
72, 63% (54-72)Abnormal Gfr,
43, 37% (28-46)
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Table 2
 Proportion of patients with low GFR in various malignancies
Malignancy                                                       Proportion with abnormal   
	 GFR(95%	 Confidence	 interval
All  29.3 (15.0-43.5) 
Myeloid Leukemia  50.0 (49.0-149.0) 
Non-Hodgkins  27.8 (6.3-49.3) 
Hodgkins  14.3 (-14.0-42.3) 
Wilms Tumour  57.1 (29.9-84.3) 
Other Solid Tumours  58.3 (28.9-87.8) 
Retinoblastoma  40.0 (-8.5-88.5) 
Rhabdomyosarcoma  35.7 (9.4-62.0) 
Total  43 
There	was	a	 low	glomerular	filtration	 rate	 in	29%	
of the children with leukemia, 57% in wilms tumor, 
58% in solid tumors and 40% in rhabdomyosarcoma 
and at least 14% in all the other tumors. However, 
the	 estimates	 had	 very	wide	 confidence	 intervals	
because of the small numbers (Table 3). Solid tumor 
patients (including wilms, retinoblastoma  and 
rhabdomyosarcoma) had a large proportion of 
patients with abnormal GFR.
The main nephrotoxic drugs used in KNH cancer 
treatment protocols are the platinum based compounds 
(cisplatin and carboplatin) and the alkylating agents 
(cyclophosphamide and ifosfamide. Figure 3 shows the 
GFR median values for the cytotoxics. We see that for 
all drugs, there was a minimum of 30% prevalence in 
decline in the GFR, i.e is either below or bordering on 
60ml/min/1.73m2. Ifosfomide had the highest number 
of patirnts with abnormal GFR. 
Figure 3
Frequency of patients with abnormal GFR on various chemotherapeutic drugs 
Table 3
 Creatinine and GFR changes following at least 6 months of chemotherapy 
Kidney Period median IQR p-value
Creatinine(mmol Before 49.0 37 to 63 <0.001
 After 66.0 50 to 79 
GFR(ml/min) Before 123.0 86 to 167 <0.001
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At the long-term assessment of GFR, patients had 
significantly	 lower	 renal	 function	 values	 after	 at	
least six months of treatment than the beginning of 
treatment p<0.001.  Initial GFR had a median value 
Figure 4












Association between GFR and Selected Risk Factors 
Risk Factor GFR Status  OR 95% CI  p-value
 Abnormal,  Normal,
 (43) n(%) (72) n(%)    
Treatment Regimen       
None of the Nephrotoxic drugs 8 (19) 11 (15)    
Drugs Cisplatin/Cyclopho-
sphamide/both 35 (81) 61 (85) 1.3 (0.5 to 3.4) 0.642
Type of Malignancy        
Leukemia 13 (30) 30 (42) 0.7 (0.3-1.5)  0.348
Lymphoma 8 (19) 17 (24) 0.5 (0.2-1.4) 0.169
Solid 22 (51) 25 (35) 2.2 (1.7 to 4.9) 0.038
Sex        
Male 23 (53.5) 46 (63.9)    
female 26 (46.5) 26 (36.1) 1.5 (0.7-3.3) 0.271
Course        
<=10 23 (53.5) 33 (45.8)    
10+ 29 (46.5) 39 (54.2) 0.7 (0.3-1.5) 0.427
Age        
< 5 16 (37.2) 14 (19.4) 1  
5-8 18 (41.9) 32 (44.4) 2.0 (0.7-5.7) 0.129
8+ 9 (20.9) 26 (36.1) 3.3 (1.0-10.8) 0.023
of 123 ml/min/I .73 m2 (range 86-167). Final median 
GFR was 102 ml/min/1.73 m2 (range 84-127). Two 
years was the longest duration of treatment in the 
study patients. (Figure 4)
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The type of chemotherapeutic agent used, the sex and 
the courses of treatment did not confer a great risk to 
development of a decline in GFR. Nevertheless the 
type of malignancy conferred a double likelihood of 
developing an abnormal GFR. There was a positive 
trend in association in that the older one was the 
less likelihood of developing an abnormal GFR as 
shown in Table 4.
DISCUSSION
The pattern of malignancies among our study patients 
was Leukemia 43(37%) in children, followed by 
children with Burkitts lymphoma 18(16%), children 
with Wilms tumor and Rhabdomyosarcoma 14(12%) 
each. Other malignancies were Retinoblastoma, Kaposi 
sarcoma, Hodgkin’s Lymphoma and other solid tumors 
(Neuroblastoma, Osteogenic sarcoma and Yolk sac 
tumors. Highest number of malignancies was seen 
in	 the	 age	 group	 between	five	 to	 eight	 years	 .This	
compares to a study done in indigenous Zambian 
children where the pattern of malignancies seen 
during a ten year period(1980-1989), revealed a total 
of	 525	neoplasms	with	peak	prevalence	 in	 the	five	
to nine year age group. Non-Hodgkin’s lymphoma 
(17.5%) was the most common disorder followed by 
Burkitt’s lymphoma (13.9%), retinoblastoma (11.4%), 
Kaposi’s sarcoma (8.8%), Hodgkin’s disease (5.9%), 
Wilms’ tumour (5.9%), acute lymphocytic leukaemia 
(4%), rhabdomyosarcoma (3.4%), nasopharyngeal 
carcinoma (2.7%) and osteogenic sarcoma (2.1%). (5)
 The point prevalence of abnormal glomerular 
filtration	 rates	 in	 children	 on	 treatment	 for	 cancer	
was 37% (95%CI 26.8-44.5). Nephrotoxicity was 
observed in a substantial proportion of patients. This 
represented a third of the patients on treatment and 
has a higher frequency than previously documented 
in other studies. The relative risk of developing a 
decline in GFR while on nephrotoxic chemotherapy 
has been documented as 21% by Pinkerton et al (6). 
The postulated reasons of this are higher rates of 
malnutrition and sepsis which are conditions that 
also interfere with kidney function and decrease GFR, 
further studies would be required to ascertain this.  
 There was a greater predisposition of younger 
patients to the development of nephrotoxicity as seen 
both in our study and Ashraf et al. In the paediatric 
patient, developmental changes occurring from 
term to 3 to 5 years of age affecting proximal tubular 
function and, to a lesser degree, glomerular function 
may increase the vulnerability of young kidneys to 
toxic insults.(7) 
 Children with solid tumors including Wilms 
tumour had a high prevalence of abnormal GFR; these 
can be attributed to the fact that they receive both 
nephrotoxic drugs that is, platinum and alkylating 
agents in their treatment regimes. In the study the 
main solid malignancies in the group were osteogenic 
sarcoma, rhabdomyosarcoma, retinoblastoma and 
neuroblastoma. The GFR of 40% of these patients 
was decreased (P-value of 0.038). Use of cisplatin 
concurrently with other nephrotoxic agents, 
particularly ifosfamide, increases the risk of renal 
injury (8); Hartmann et al performed a randomised 
trial comparing the nephrotoxicity of cisplatin/
ifosfamide-based combination chemotherapy with or 
without amifostine(medicine is used to decrease the 
side effects of certain cancer or radiation therapies) in 
patients with solid tumors. In the amifostine-group 
GFR was fully maintained after application of two 
cycles of chemotherapy, whereas in the control group 
a > 30%-reduction of median GFR (108 to 80 ml/min) 
was observed (p < 0.001). 
	 We	confirm	previous	observations	that	cisplatin-
based chemotherapy leads to decrease in renal 
function ,40% of patients on platinum based therapy 
had a GFR of <60 ml/min. Kintzel et al showed 67% in 
patients with GFR <60 ml/min(9). Our mean decrease 
in	 renal	 function	of	 14%	confirms	 the	observation	
of Jones et al (10) who reported a 15% reduction of 
creatinine	 clearance	 after	 five	 cycles	 of	 cisplatin-
based chemotherapy. Our percentage of patients 
with impaired renal function after was chemotherapy 
(36%).
 Cisplatin and carboplatin cause dose-related 
renal dysfunction. In addition to increased serum 
creatinine levels and uraemia as shown by Kintzel et 
al. The concentration of cisplatin during the days of 
chemotherapy has also been discussed as a predictor 
of the development of reduced renal function. The 
cumulative dose rather than the serum concentration 
of cisplatin seems to be responsible for the reduction of 
renal function in the oncology patients.  Retrospective 
analysis of 22 patients with testicular cancer treated 
with 1 to 5 cycles of cisplatin-based chemotherapy 
reported a reduction in mean GFR from 137 ml/min 
to 106 ml/min (11). GFR was evaluated in patients 
who had received a cumulative cisplatin dose of 180 
to 900mg, renal function become more impaired, even 
though only three chemotherapy cycles had been 
applied. Long-term effects of continuously elevated 
serum concentrations of cisplatin (12) may also, 
over years, reduce renal function. 43% of patients in 
our study on platinum based regimens had a GFR 
of less than 60 ml/min/1.73 m2. Fossa et al showed 
a reduction of mean GFR from 109 ml/min to 68 
ml/min following three 21 day cycles of cisplatin 
200 mg/m2 (40 mg/m2/day for 5 days) is reported.
(13). Total cumulative dose of cisplatin in patients 
in the study was ranging from 612-7333mg/m2. Use 
of cisplatin concurrently with other nephrotoxic 
agents, particularly ifosfamide, increases the risk 
of renal injury. Long-term effects of continuously 
elevated serum concentrations of cisplatin may also, 
over years, reduce renal function. In this regard, 
clinicians should be aware that serum levels of 
creatinine	do	not	sufficiently	mirror	the	changes	in	
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renal function, as demonstrated by previous reports. 
Cyclophosphamide and ifosfamide are alkylating 
agents	which	have	been	incorporated	into	firstline	
therapy for a number of malignant paediatric 
tumours. Recent data appears to suggest that tubular 
dysfunction may result from incorporation of this 
drug into chemotherapy schedules and that toxicity 
may be dose related.In the present study,out of the 
95 patients who were on alkylating agents 40% had 
abnormal renal function and  cumulative doses of 
cyclophosphamide ranged from 875-15 500mg/m2. 
Ifosfamide has been shown to be more nephrotoxic 
than cyclophosphamide. 
 A number of risk factors for chronic ifosfamide 
nephrotoxicity have been proposed. These include 
cumulative dose (> 60-100 g/m2), age < 3-5 years, 
concurrent or previous platinum therapy. The most 
important predictive risk factor for toxicity appears to 
be the cumulative dose of ifosfamide( 8).Cumulative 
cyclophosphamide dose exceeding 1000mg/m2 and 
patient age are the 2 greatest predictors of risk for 
development of nephrotoxicity (14). The likelihood 
of renal dysfunction increases as the cumulative dose 
of cyclophosphamide increases.
 In addition, the incidence and severity of 
nephrotoxicity is greater in patients younger than 
5 years. Skinner et al who evaluated 174 paediatric 
patients (median age 8.7 years, range 0.4 to 21 
years) receiving treatment with monthly ifosfamide 
(median cumulative dose 45.5 g/m2, range 12.4 to 
76.6 g/m2) revealed that the median age of patients 
developing severe drug-induced nephrotoxicity 
was 2.2 years compared with 7.0, 8.2 and 10.5 
years for patients experiencing moderate, mild and 
no nephrotoxicity, respectively (15). Previous or 
concurrent administration of cisplatin increases the 
risk of nephrotoxicity. In fact, increased cumulative 
cisplatin dose has been associated with increased 
severity of ifosfamide-induced renal dysfunction. 
Judicious monitoring of patients on treatment and 
discontinuation of this agent when generalised, albeit 
subclinical, dysfunction is documented, may well be 
warranted.  Nephrotoxicity occurs primarily with 
high dose methotrexate therapy; however, it can also 
occur with long-term administration of conventional 
dose methotrexate (16). Acute tubular necrosis 
subsequent to crystallisation of the parent drug and 
the metabolite 7-hydroxymethotrexate within renal 
tubules is the purported underlying mechanism 
of methotrexate-induced renal dysfunction.All the 
patients on methotrexate were found to have an 
abnormal GFR.
	 There	was	a	statistically	significant	change	in	both	
the creatinine and GFR before and after in children on 
cancer chemotherapy at KNH. The number of patients 
with abnormal kidney function at the beginning and 
the end of the study was 30 and 43 which shows that 
there is a decline in renal function following cancer 
chemotherapy. Initial GFR had a median value of 123 
ml/min/I .73 m2 (range 86-167). Final median GFR 
was 102 ml, 1.73 m2 (range 84-127). A statistically 
significant	fall	in	GFR	is	observed	in	43	patients	(36%)	
(Mean	[95%	confidence	limits]	fall	35.1	[22.1–47.9]	ml/
min/ 1.73 m2; paired t-test, t = 8.96 p-value = 0.036
 The above results have been duplicated in other 
studies. Pinkerton et al showed a median reduction in 
GFR of 32 ml/min/1.73 m2 (-46 to 134). Measurement 
of creatinine clearance at six month intervals in 15 
patients with testicular cancer receiving three or 
more cycles of cisplatin 100 mg/m2 (20 mg/m2/day for 
five	days)	repeated	every	21	days	revealed	a	reduction	
in mean creatinine clearance from 112 ml/min to 68 
ml/min during the initial 6 month period following 
initiation of treatment (43). Retrospective analysis of 
22 patients with testicular cancer treated with 1 to 5 
cycles of cisplatin-based chemotherapy reported a 
reduction in mean GFR from 137 ml/min to 106 ml/
min (17).
 The decrease in median GFR in comparison with 
the pretreatment value was 15.5% at the start of the 
maintenance therapy, 23% at the end of the maintenance 
therapy and 15.5% 1 year after termination of therapy 
shown by Meijer et al who determined GFR Glomerular 
filtration	rate	(GFR)	in	eight		patients	with	disseminated	
testicular carcinoma before, during and one year 
after termination of a combination of chemotherapy 
with cis-diamminedichloroplatinum (CDDP).  At all 
intervals	the	changes	in	GFR	were	significantly	reduced	
in comparison with pretreatment values (18).
In conclusion, the harmful side effects of the various 
chemotherapeutic agents versus their useful anticancer 
effects present a challenge in management. With 
regard to long-term survivors, the possible effects of 
treatment and their consequences on the quality of 
life are a major concern. Kidney disease frequently 
complicates malignancy and its treatment.
 Our study showed that a third of our patients 
who had been on cancer chemotherapy had a GFR 
less than 60 ml/min and a decline in GFR occurs as 
ongoing cancer chemotherapy  is given. Monitoring 
of kidney function should be done on a regular basis 
especially	for	the	young	(below	five	years)	and	those	
with solid tumors. The age of the patient is poses a risk 
for nephrotoxic damage due to immature structural 
development	of	 the	kidney	 in	 those	 less	 than	five	
years. Patients with solid tumors receive 12 courses 
of combination chemotherapy in which cumulative 
doses of both platinum compounds and alkylating 
agents are known to cause kidney damage.
 Function and quality of life may be impaired 
and exposure-based risk assessment is key for 
identification	 of	 long-term	 renal	 complications.	
Timely and appropriate treatment, often coordinated 
with a nephrologist, may diminish symptoms and/
or prevent further damage.
EAMJ GLOMERULAR FEBRUARY 2012.indd   51 5/28/13   1:46:17 PM
52 East african MEdical Journal February 2012 
REFERENCES
Stiller, C. A. and Parkin, D. M. Geographic and ethnic 1. 
variations in the incidence of childhood cancer. Br. 
Med. Bull. 1996; 52: 682-703.  
Parkin, D. M. and Bieber, C. A. The international 2. 
incidence of childhood cancer. Int. J. Cancer.  1988; 
42: 511-520.
Macharia, W. M. A review of childhood cancers in a 3. 
National Referral Hospital. East. Afr. Med. J. 1996; 73: 
647-650.
Kintzel, P. E. Incidence, Prevention and Management 4. 
Renal Failure Associated with Cancer and Its Treatment. 
Drug Safety 2001; 24: 19-38. 
Skinner, Pearson, Malcolm, 5. et al. Assessment of 
chemotherapy-associated nephrotoxicity in children 
with cancer. Cancer chemotherapy and pharmacology 
1991; 28: 81-92.
Makata, 6. et al. The pattern of paediatric solid malignant 
tumours in Western Kenya in 1979-1994.  Amer. J.  Tropic. 
Med. Hygiene. 1998; 32:  42-45.
Pinkerton, et al. Chemotherapy for stage 4 neuroblastoma 7. 
in children over 1 year of age. Med Paed. Onco. 2001; 
36: 239-242.
Ashraf, 8. et al. Ifosfamide nephrotoxicity in paediatric 
cancer patients. Eur. J. Pediatr. 1994; 153: 90-94.
Loebstein, R., Atanackovic, G., Bishai, R., 9. et al. Risk 
factors for longterm outcome of ifosfamide induced 
nephrotoxicity in children. J. Clin. Pharmacol.  1999; 
39: 454–461.
Deborah, P., Sheri, L., Spunt., 10. et al. Review Renal Late 
Effects in Patients Treated for Cancer in Childhood. 
Pediatr. Blood Cancer. 2008; 51: 724–731.	
Macleod, P. M., Tyrell, C. J. and Keeling, D. H. The 11. 
effect of cisplatin on renal function in patients with 
testicular tumors. Clin. Radiol.  1988; 39: 190-192. 
Portilla, D., Li. S., Nagothu, K. K. 12. et al. Metabolomic 
study of cisplatin-induced nephrotoxicity. Kidney Int. 
2006; 69: 2194-2204.
Fosså, S. D., Aass, N., Winderen, M., 13. et al. Long-term 
renal function after treatment for malignant germ-cell 
tumours. Ann Oncol.  2002 Feb; 13: 222-228.
DeFronzo.,  Colvin.,  Braine, 14. et al. Cyclophosphamide 
and the kidney. Cancer. 1974; 33: 483.
Skinner, R., Cotterill, S. J. and Stevens, M. C. Risk 15. 
factors for nephrotoxicity after ifosfamide treatment 
in children. Br. J. Cancer. 2000; 82: 1636–1645.	
Fox, R. M. Methotrexate nephrotoxicity. 16. Clin. Exp. 
Pharmacol. Physiol. 1979; 5: 43-45. 
Womer, R. B., Pritchard, J. and Barratt, T. M. Renal 17. 
toxicity of cisplatin in children. J. Pediatr. 1985; 106: 
659–663.
Meijer,  18. et al. Some effects of combination chemotherapy 
with cis-platinum on renal function in patients with 
non seminomatous testicular carcinoma. Cancer. 1983; 
51:		2035–2040.
EAMJ GLOMERULAR FEBRUARY 2012.indd   52 5/28/13   1:46:18 PM
